CareDx Inc - Asset Resilience Ratio
CareDx Inc (CDNA) has an Asset Resilience Ratio of 23.78% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read CDNA total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2024)
This chart shows how CareDx Inc's Asset Resilience Ratio has changed over time. See CareDx Inc book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down CareDx Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CareDx Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $102.78 Million | 23.78% |
| Total Liquid Assets | $102.78 Million | 23.78% |
Asset Resilience Insights
- Good Liquidity Position: CareDx Inc maintains a healthy 23.78% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
CareDx Inc Industry Peers by Asset Resilience Ratio
Compare CareDx Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Eurofins-Cerep SA
PA:ALECR |
Diagnostics & Research | 6.56% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Imagion Biosystems Ltd
AU:IBX |
Diagnostics & Research | 150.16% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for CareDx Inc (2012–2024)
The table below shows the annual Asset Resilience Ratio data for CareDx Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 29.72% | $145.96 Million | $491.05 Million | -3.10pp |
| 2023-12-31 | 32.82% | $153.22 Million | $466.83 Million | -4.59pp |
| 2022-12-31 | 37.42% | $203.17 Million | $542.99 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $566.62 Million | -- |
| 2020-12-31 | 24.43% | $90.03 Million | $368.51 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $83.56 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $76.73 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $55.64 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $61.14 Million | -- |
| 2012-12-31 | 0.30% | $30.00K | $9.88 Million | -- |
About CareDx Inc
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution … Read more